Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AHPA defends plant imports from law

This article was originally published in The Tan Sheet

Executive Summary

The Animal and Plant Health Inspection Service of the Department of Agriculture should exempt plants imported for use in foods, drugs and cosmetics from the importation disclosure requirements in the Lacey Act, the American Herbal Products Association says in comments submitted Dec. 8. The Lacey Act is intended to prevent illegal timber trade, AHPA says, but could affect herbal imports due to language in the 2008 federal farm subsidy programs reauthorization (1"The Tan Sheet" May 19, 2008, p. 11). AHPA is concerned the act's expanded jurisdiction over plants, plant parts and plant products "will result in filing of ... unnecessary and largely redundant information for plants that are neither timber nor derived from timber," President Michael McGuffin says

You may also be interested in...



Farm Bill Grows Herbal Crop Support, But No Vitamins In Food Stamp Program

Congress added financial support for herbals and other specialty crops to the federal farm subsidy programs reauthorization, but omitted multivitamins from food stamp coverage for the second time

Pfizer AdComm Asks Many Questions About COVID Vaccine For Ages 5-11, But Gets Few Answers

Often data was not available from FDA, CDC or the sponsor to answer subgroup, safety and other questions that could have influenced the outcome of the advisory committee meeting.

Merck’s Molnupiravir Open License With Medicines Patent Pool May Be Model

Pharma industry critics herald the agreement for allowing many manufacturers around the world to make the COVID-19 therapeutic and for its transparency. If Merck can do it, they ask, why can’t other companies?

Topics

UsernamePublicRestriction

Register

PS102400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel